Lonza Consumer Health and Nutrition Granted U.S. Patent for L-Carnitine (Carniking®) in Animal Nutrition

December 05, 2018

Greenwood, SC (USA), 5 December 2018 – Lonza announced today that it has been granted U.S. Patent 10,016,382 for L-Carnitine use in pet food for its beneficial impact on performance and recovery in active dogs. Proven to help maintain lean muscle mass by reducing muscle degradation and oxidative stress resulting from intense physical exercise, the patent confirms evidence that small daily doses of Lonza’s Carniking® L-Carnitine may positively enhance quality of life and function for active dogs and working animals, such as service dogs and tracking dogs. Other applications are pending in Brazil, Canada, Europe and Japan.

L‑Carnitine’s role in helping both animals and humans utilize dietary fat for energy production is well established, namely that it shuttles long- and medium-chain fatty acids across the outer and inner-mitochondrial membrane so they can be metabolized and converted into energy. L-Carnitine has an ingredient definition by the Association of American Feed Control Officers (AAFCO) for use in the manufacturing of dog foods, wet and dry treats, and in complete feeds, base mixes or premixes.

In four canine research studies sponsored by Lonza Consumer Health & Nutrition (CHN), Carniking® L-Carnitine was shown to improve exercise performance, activity as well as lean mass, muscle recovery and oxidative stress during strenuous exercise. The latest published research in 2017 included three clinical studies conducted at Four Rivers Kennel LLC with a total of 96 Labrador Retrievers, a typical working and service dog. The studies demonstrated the significant positive benefits of L-Carnitine on post-exercise activity and body composition in these active dogs, when compared with placebo, from just one daily 250 mg dose of Carniking® L-Carnitine for a period of 14 weeks.

“Bringing together 30 years of investment and discovery in L-Carnitine, Lonza’s new patent for L-Carnitine as Carniking® highlights our continued commitment to exploring its health benefits for both animals and humans. Backed by robust science, the patent confirms that L-Carnitine is good for both you and for your dog,” said Kevin Owen, Ph.D. Global Business Development Head- Companion Animals at Lonza CHN and co-author of the patent.

More information about Carniking® and Lonza CHN’s range of ingredients for animal nutrition is available: www.carniking.com.

About Lonza

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

 Lonza Contact Details

Dirk Oehlers, Head Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540

Constance Ward, Head External Communications
Lonza Group Ltd
Tel +41 61 316 8840

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.